Compare SFBS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBS | IRON |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 2014 | N/A |
| Metric | SFBS | IRON |
|---|---|---|
| Price | $73.32 | $90.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $80.00 | ★ $108.85 |
| AVG Volume (30 Days) | 269.7K | ★ 573.4K |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ 24.86 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $497,701,000.00 | N/A |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $16.87 | N/A |
| P/E Ratio | $15.63 | ★ N/A |
| Revenue Growth | ★ 16.24 | N/A |
| 52 Week Low | $66.48 | $30.82 |
| 52 Week High | $93.90 | $99.50 |
| Indicator | SFBS | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 50.55 |
| Support Level | $73.72 | $86.75 |
| Resistance Level | $76.21 | $94.51 |
| Average True Range (ATR) | 2.05 | 3.83 |
| MACD | 0.27 | -0.85 |
| Stochastic Oscillator | 42.23 | 27.22 |
Servisfirst Bancshares Inc is a bank holding company whose business is conducted by its wholly owned subsidiary, ServisFirst Bank. Through the bank, it offers various banking services to individual and corporate customers in Birmingham, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. Its various products and service offerings include commercial, consumer, and other loans; accepting deposits; providing electronic banking services, such as online and mobile banking, including remote deposit capture; delivering treasury and cash management services; and providing banking services to other financial institutions. The company operates as a single reportable segment, with a majority of its revenue being derived from the business of banking.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.